Dianovix, Inc.

Virender Bhan

Robert G Korneluk

George S Robertson

Martin Holcik

Andrea Hebb

John W Gillard

Craig Moore

Disclosed is a method of determining interferon responsiveness in a patient suffering from multiple sclerosis. The method comprises determining an amount of a XAF-1 gene expression level in a blood sample, which is obtained from the patient undergoing interferon therapy. The amount of the XAF-1 gene expression level in the blood sample is then correlated with the responsiveness of the patient to the interferon.

Diagnostic marker for interferon responsiveness in multiple sclerosis

Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.

Method for differentiating between multiple sclerosis subtypes

Growing community of inventors

Halifax, Canada

Virender Bhan